RVMD
FDA Approves Rasonque, First RAS Inhibitor for Metastatic Pancreatic Cancer
The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.
RVMD
Market-moving news on Revolution Medicines (NASDAQ: RVMD): filings, earnings, deals and other events, from REDFILED.